ARK Investment Boosts Stake in Twist Bioscience

Institutional investor increases ownership in synthetic biology company

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

ARK Investment Management LLC, a prominent investment firm, has increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 5.1% in the third quarter, according to a recent 13F filing with the SEC. ARK now owns approximately 11.14% of Twist Bioscience, making it the company's 25th largest holding.

Why it matters

Twist Bioscience is a leading synthetic biology company that has developed a proprietary platform for high-throughput DNA synthesis. ARK's increased investment in the company signals the firm's confidence in Twist's technology and growth potential within the rapidly evolving field of synthetic biology.

The details

According to the 13F filing, ARK Investment Management acquired an additional 326,367 shares of Twist Bioscience in the third quarter, bringing its total ownership to 6,726,808 shares. This represents approximately 11.14% of Twist's outstanding shares. The investment firm cited Twist's innovative DNA synthesis platform and its potential applications in areas like therapeutics, diagnostics, and industrial biotechnology as key factors behind the increased stake.

  • ARK Investment Management filed the 13F report disclosing the increased stake in Twist Bioscience on March 5, 2026.
  • The 5.1% increase in ARK's ownership of Twist Bioscience occurred during the third quarter of the previous year.

The players

ARK Investment Management LLC

A prominent investment management firm that focuses on disruptive innovation across sectors like technology, healthcare, and finance.

Twist Bioscience Corporation

A synthetic biology company that has developed a proprietary platform for high-throughput DNA synthesis, with applications in areas like therapeutics, diagnostics, and industrial biotechnology.

Got photos? Submit your photos here. ›

The takeaway

ARK Investment Management's increased stake in Twist Bioscience underscores the firm's confidence in the company's technology and growth prospects within the rapidly evolving synthetic biology industry. This investment highlights the potential of Twist's DNA synthesis platform to drive innovation across a range of applications.